ArticleMolecular pharmaceutics2018
Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Hypoxia Exacerbates Inflammatory Signaling in Human Coronavirus OC43-Infected Lung Epithelial Cells.Biomolecules · 2025Article
- Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics.RSC advances · 2025Review
- Radionuclide-based theranostics - a promising strategy for lung cancer.European journal of nuclear medicine and molecular imaging · 2023Review
- Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment.Cancers · 2023Article
- Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.Molecular pharmaceutics · 2023Article
- Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.Frontiers in immunology · 2023Article
- Dive into the details of radionuclide antibody conjugates: what role do EPR effects and LETs of different radionuclides play?American journal of nuclear medicine and molecular imaging · 2023Article
- Review
- Article
- Radiotheranostic Agents in Hematological Malignancies.Frontiers in immunology · 2022Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- Antibody-Drug Conjugates for Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.Advanced functional materials · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases.Chembiochem : a European journal of chemical biology · 2019Review
- ImmunoPET imaging of CD38 expression in hepatocellular carcinoma usingAmerican journal of translational research · 2019Article
- Immuno-PET imaging of VEGFR-2 expression in prostate cancer withAmerican journal of cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
CD30 has been considered a unique diagnostic and therapeutic target for CD30-positive lymphomas and some lung diseases. Additionally, CD30 has shown high expression in clinical lung cancer samples. In this study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.